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Background: Toxoplasmosis, caused by the obligate intracellular parasite Toxoplasma gondii, is an important
zoonotic disease worldwide. The precise detection of T. gondii infection in dogs has important public health
significance. In this study, recombinant granule antigen proteins GRA1 and GRA7 were evaluated as potential
diagnostic markers for T. gondii infection in dogs by an indirect enzyme-linked immunosorbent assay (ELISA).
Results: GRA1 and GRA7 were cloned and expressed in Escherichia coli, and the recombinant GRA1, GRA7- and
Toxoplasma lysate antigen (TLA)-based ELISAs were developed and evaluated using the canine positive and
negative serum samples for anti-T. gondii antibodies determined by modified agglutination test (MAT) and indirect
fluorescent antibody test (IFAT), showing a seroprevalence of 15.1% by TLA- and GRA1-ELISA, and 15.8% by GRA7-ELISA,
and no significant difference was observed (P > 0.05). When compared with the two reference assays, MAT and IFAT,
the GRA7-ELISA showed the highest co-positivity and co-negativity rates. Receiver operating characteristic (ROC)
analysis revealed a largest area under curve (AUC) of 0.973 (95% CI, 0.955 to 0.991), and a highest relative sensitivity
(93.2%) and specificity (94.0%) for a cut-off value of 0.809 in GRA7-ELISA.
Conclusions: The results of the present study showed that GRA7-ELISA is highly sensitive and specific, and GRA7
is a potential serodiagnostic marker for the detection of T. gondii infection in dogs.
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Toxoplasma gondii, an obligate intracellular parasite, can
infect virtually all warm-blooded animals, including
humans. Humans and animals become infected by eating
undercooked or raw meat containing cysts, or by con-
suming food contaminated with sporulated oocysts [1].
Understanding the prevalence of T. gondii infection in
dogs is of economic and public health importance.
Firstly, the infection is serious in young dogs, especially
in those co-infected with canine distemper virus [2].
Secondly, dogs are potentially involved in the mechan-
ical transmission of T. gondii oocysts to humans, and* Correspondence: xingquanzhu1@hotmail.com; liuquan1973@hotmail.com
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unless otherwise stated.shed parasite in their saliva [3-5]. Thirdly, in regions
where dogs are used as food animals, T. gondii can be
transmitted to humans by consumption of undercooked
meat from infected dogs [6]. Lastly, dogs are the most
common pets in the world, and also reflect the extent of
T. gondii infection in the domestic environment [7].
Definitive diagnosis of T. gondii infection by mouse
inoculation, or immunohistochemical analyses is opti-
mal. However, these tests are time-consuming, involved
in experimental animals, and may have a low sensitivity
[8]. Multiple tests, such as indirect haemagglutination
(IHA), modified agglutination test (MAT), latex agglu-
tination test (LAT), indirect fluorescent antibody test
(IFAT), and enzyme-linked immunosorbent assay (ELISA),
are useful to demonstrate T. gondii infection in humans
and animals. Despite the satisfactory results of serological
tests, development of reliable and standard reagents
remains a major constraint in serodiagnosis of T. gondii
infection. Most conventional tests using tachyzoitestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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standardize, making the test results difficult to evaluate [9].
T. gondii dense granule antigen proteins (GRAs) are
secretory proteins expressed by both tachyzoite and
bradyzoite [10]. GRA1 is secreted into the parasitophor-
ous vacuole (PV), which has Ca2+ binding domain, becom-
ing a physiological important factor to invade in the host
cells [11], and GR7 is secreted into the cytoplasm of
bradyzoite-infected cells and within the PV and the PV
membrane in tachyzoite-infected cells [12]. GRA1-based
ELISA shows a sensitivity of about 60%, but the specificity
can reach 98% in humans [13,14]. GRA7 based-ELISA has
presented overall specificity of 98 to 100% and sensitivity
of 81 to 88% in humans and goats [15,16]. Moreover,
GRA7-ELISA has the highest positive rate in pregnant
women, compared with the rhoptry (ROP1), matrix anti-
gens (MAG1), the major surface antigen (SAG1), and
GRA8 [17]. However, there are few reports on evaluation
of GRAs as potential diagnostic markers for T. gondii in-
fection in dogs. In the present study, recombinant proteins
GRA1 and GRA7 were expressed and evaluated for sero-
diagnosis of T. gondii infection in dogs by indirect ELISA.
Methods
Ethics statement
The pet dogs from which blood were collected, were han-
dled in accordance with good animal practices required
by the Animal Ethics Procedures and Guidelines of the
People’s Republic of China. The client owned pet dogs
were admitted into pet hospitals in Lanzhou City, Gansu
province, Northwest China. Consent was obtained from
the owners of the pet dogs. The present study was
approved by the Animal Ethics Committee of Lanzhou
Veterinary Research Institute, Chinese Academy of Agri-
cultural Sciences (Approval No. LVRIAEC2010-005).
Preparation of Toxoplasma lysate antigen (TLA)
T. gondii soluble antigens (TLA) was prepared by sonic-
ating the purified T. gondii tachyzoites of GT1 strain,
and diluted to a final concentration of 1 mg/ml in PBS
as described elsewhere [18].
Expression and purification of recombinant GRA1 and GRA7
Based on the nucleotide sequence of GRA1 (HM067753)
and GRA7 (JX045574), the PCR primers for amplifica-
tion of the gene products of 570-bp GRA1 (forward:
5′-AACCATGGTGCGTGTGAGCGCTATTG-3′; reverse:
5′-GCGAATTCCCTCTCTCTCTCCTGTTAGGAAC-3′)
and 675-bp GRA7 (forward: 5′-ATTCCATGGCGGCC
ACCGCGTCAGAT-3′; reverse: 5′-GCGAATTCCTCTT
CTGTGTCTGTCTGCCTCTC-3′) were designed. The
italics in the primer sequences represented the EcoRI
and NcoI linker sites in the expression vector pET-28a
(Novagen). The PCR was performed at an annealingtemperature of 58˚C for 45 s. The resulting gene prod-
ucts were cloned into the EcoR1/NcoI site of pET-28a to
generate a recombinant plasmids pET28-GRA1 and
pET28-GRA7, which were confirmed by restriction
enzymes and sequencing, and further processed for the
expression of recombinant products in Escherichia coli
BL21 (DE3) according to the standard techniques.
The recombinant proteins were analyzed by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) using a 12% polyacrylamide gel. The reactivity
with T. gondii positive sera was tested by immunoblot.
Blots of recombinant GRA1 and GRA7 were incubated
with T. gondii-positive mice sera, followed by alkaline
phosphatase-conjugated goat anti-mouse antibodies. The
recombinant GRA1 and GRA7 were purified using a
Ni-NTA purification system (Qiagen, Germany) according
to the manufacturer’s protocol.
Serum samples
A total of 259 blood samples were collected from dogs
between November and December 2010 in Lanzhou,
China. Sera were separated by centrifugation at 1,500 × g
for 10 min and stored at −20°C until use. The positive and
negative samples for T. gondii infection were determined
by MATand IFAT [19-21].
ELISA
Indirect ELISA was performed to test T. gondii infection
in dogs as described by elsewhere [22]. Briefly, micro-
plates were coated with TLA, GRA1, or GRA7, respect-
ively. After washing, 100 μl of canine serum diluted 1:50
was added to each well, and incubated for 3 h at 37°C,
then 100 μl of horseradish peroxidase-conjugated sheep
anti-dog IgG antibodies (Abcam, USA) diluted 1:20,000
was added. After incubation for 1 h at room temperature
and washing, color was developed by the addition of
a substrate solution containing tetramethylbenzidine
chromogenic substrate TMB (Thermo Fisher Scientific,
USA), and stopped by 2 M H2SO4. The optical densities
(ODs) were measured at 450 nm in a microplate reader
(BioTek, USA). ELISA results were determined for each
serum in duplicate. The cut-off point of OD values of a
positive samples was set to be at least two times higher
than that of the negative samples at any dilution point.
Data analysis
The significance of association between the results of
ELISAs was analyzed using the McNemar chi-square test.
The degree of agreement between the results from the 2
tests was quantified using Kappa statistics. Sensitivity and
specificity of ELISA was determined as described by
elsewhere [23]. The expected performance of the ELISAs
at different cut-off points was examined using the receiver
operating characteristic (ROC) curves [24].
Figure 1 Western blotting analysis of the recombinant GRA1
and GRA7 expressed in E. coli. Lane 1: molecular protein marker;
Line 2: the expressed GRA7; Line 3: the expressed GRA1; Line 4: control
culture of cells lacking the GRA1 or GRA7 insert.
Table 2 Prevalence of Toxoplasma gondii antibody and








No. (%) of samples showing
the antibody titers at
1:50 1:100 ≥1:200
TLA-ELISA 259 42 (16.2) 25 (9.7) 8 (3.1) 9 (3.5)
GRA1-ELISA 259 42 (16.2) 25 (9.7) 7 (2.7) 10 (3.9)
GRA7-ELISA 259 44 (17.0) 26 (10.0) 9 (3.5) 9 (3.5)
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Expression and purification of recombinant T. gondii
GRA1 and GRA7
The GRA1 and GRA7 encoding genes were amplified,
and cloned into expression vector pET-28a to construct
recombinant plasmids pET28-GRA1 and pET28-GRA7,
which were transformed into Escherichia coli BL21 (DE3),
and induced by IPTG. The immunoreactivity of theTable 1 Detection results of Toxoplamsa gondii
antibodies in dogs by ELISA based on TLA, GRA1 and
GRA7
MAT and IFAT
No. of positive No. of negative Total
TLA-ELISA
No. of positive 37 5 42
No. of negative 7 210 217
Total 44 215 259
GRA1-ELISA
No. of positive 34 8 42
No. of negative 10 207 217
Total 44 215 259
GRA7-ELISA
No. of positive 39 5 44
No. of negative 5 210 215
Total 44 215 259expressed proteins was confirmed by Western blot ana-
lysis using the mice sera positive for anti-T. gondii IgG
antibodies (Figure 1). The recombinant proteins GRA1
and GRA7 were purified using a Ni-NTA purification
system, showing the purity of more than 95%.Evaluation of the diagnostic performance of TLA, GRA1
and GRA7
To evaluate the potential of recombinant proteins for
serodiagnosis of T. gondii infection in dogs, three
separate ELISAs were developed using TLA, GRA1
and GRA7 as coating antigens. The optimal working
dilution, determined by checkerboard assays using ser-
ial dilutions of antigens and sera, was shown 10 μg/ml
for TLA, and 5 μg/ml for both GRA1 and GRA7.
The canine serum samples were detected for anti-T.
gondii antibodies by MAT and IFAT, showing that there
were 44 positive samples and 215 negative samples.
These samples were tested by TLA-, GRA1-, and GRA7-
ELISA, respectively. As shown in Table 1, there were 42
positive and 217 negative samples by TLA- and GRA1-
ELISA, while there were 44 positive and 215 negative sam-
ples tested by GRA7-ELISA (Table 1), demonstrating that
the seroprevalence was 16.2% by TLA- and GRA1-ELISA,
and 17.0% by GRA7-ELISA (Table 2). There was no
significant difference between positive and negative results
when comparing TLA-ELISA with GRA1-, and GRA7-
ELISA results using McNemar chi-square (P > 0.05). A
substantial agreement (90.7%) was found between TLA-
and GRA1-ELISA (κappa = 0.66; 95% confidence interval
[CI], 0.53 to 0.79), and a perfect agreement (94.6%) was
observed between TLA- and GRA7-ELISA (κappa = 0.80;
95% confidence interval [CI], 0.71 to 0.90).Table 3 Comparison of diagnostic performance of ELSIA
based on TLA, GRA1 and GRA7
Detection
method






TLA-ELISA 88.1 96.8 11.9 3.2
GRA1-ELISA 81.0 95.4 19.0 4.6
GRA7-ELISA 91.0 97.7 9.0 2.3
Figure 2 Receiver operating characteristics (ROC) analysis of
the ELISAs. ROC analysis showed an area under the curve (AUC) of
0.948 (95% CI, 0.911 to 0.986) for TLA-ELISA, 0.957 (95% CI, 0.919 to
0.995) for GRA1-ELISA, and 0.973 (95% CI, 0.955 to 0.991) for
GRA7-ELISA, respectively.
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MAT and IFAT, 5 false positive and 7 false negative
samples were found in TLA-ELISA, 8 false positive
and 10 false negative samples were found in GRA1-
ELISA, and 5 false positive and 5 false negative samples
were found in GRA7-ELISA (Table 1), demonstrating that
the GRA7-ELISA showed the highest co-positivity and
co-negativity rates (Table 3).
ROC analysis
ROC analysis revealed an area under curve (AUC) of
0.948 (95% CI, 0.911 to 0.986) for TLA-ELISA, 0.957
(95% CI, 0.919 to 0.995) for GRA1-ELISA, and 0.973
(95% CI, 0.955 to 0.991) for GRA7-ELISA, respectively
(Figure 2). The estimated sensitivities and specificities
for different OD ratio cut-off values were obtained from
ROC analysis (Figure 3), indicating that the cut-off valueFigure 3 Relative sensitivity and specificity of TLA- GRA1 and GRA7-E
of 0.568 for TLA-ELISA. (B) Vertical line shows the selected cut-offs of 0.745
for GRA7-ELISA.at 0.568 for TLA-ELISA shows a sensitivity of 84.1% and
a specificity of 97.7%, and 0.745 for GRA1-ELISA shows
a sensitivity of 91.0% and a specificity of 94.0%, and
0.809 for GRA7-ELISA shows a sensitivity of 93.2% and
a specificity of 94.0%, which were considered as the most
appropriate cut-off for the 3 tests.
Discussion
Diagnosis of toxoplasmosis by demonstration of T. gon-
dii is usually difficult. Bioassays using mice or cats are
not suitable for rapid detection or field application, due
to their price, sensitivity and the length of time to reach
the results. Serological tests are still considered useful
for evaluation of the infection in humans and animals.
IHA, MAT, LAT, IFAT and ELISA have been used to de-
tect T. gondii infection in dogs [4,25-28]. However, the
sensitivity and specificity of these tests may vary between
sampling methods, or reference populations, even when
the same tests are used in different species. IHA has
poor sensitivity and concordance when compared with
ELISA, precluding their use for detection of T. gondii in-
fection in dogs [29]. MAT is the most widely used
methods for detection of T. gondii infection worldwide,
as it is not species specific. However, MAT shows high
false negative rate, and low agreement in dogs compared
with IFAT and ELISA [20,30]. IFAT is one of the most
widely used methods for detecting anti-T. gondii anti-
bodies, but it is conduct only in reference laboratories,
or by laboratory technicians that have enough experi-
ence for this test [31]. Thus, ELISA is recommended to
detect T. gondii infection in dogs [30].
Most commercial ELISAs using native tachyzoite
antigens may vary significantly between laboratories, or
between batches. An alterative approach is to develop
serological tests using recombinant proteins, with an ad-
vantage of the precise antigen composition, and easy
standardization [32]. Many recombinant antigens have
been produced and evaluated for serodiagnosis of T.
gondii infection in humans and animals, including sur-
face antigens (SAG1, and SAG2), rhoptry proteins
(ROP2, and ROP4), microneme proteins (MIC1, andLISA at different cut-offs. (A) Vertical line shows the selected cut-offs
for GRA1-ELISA. (C) Vertical line shows the selected cut-offs of 0.809
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GRA5, GRA6, GRA7, and GRA8) [32,33]. Among these
antigens, GRA1 is a major secretory antigen in chronic
infection, and GRA7 induces a very strong antibody
response in the acute infection [33]. In the present
study, recombinant GRA1 and GRA7 were evaluated for
serodiagnosis of T. gondii infection in dogs by indirect
ELISA, whose results were compared with TLA-ELISA.
A substantial agreement (>90.0%) was observed among
the 3 tests. If the detection results of MAT and IFAT
were used as references, GRA7 showed high sensitivity
and specificity as well as low FPR and FNR in compari-
son to GRA1 and TLA, suggesting that GRA7 is a good
serological marker for the detection of T. gondii infec-
tion in dogs.
GRA7 is expressed by all developmental stages, includ-
ing tachyzoites and bradyzoites, and is abundant on the
surface and cytoplasmic matrix of host cells, the PVM,
and within the PV lumen [17]. GRA7 can be used to
detect anti-T. gondii antibodies in chronic and acute
infection, but it is more associated with acute infection
[34,35]. In humans infected with T. gondii, GRA7 ap-
pears significantly earlier than other antigens, such
SAG1 and MAG1 [36,37]. When GRA7 is released
from tachyzoites and bradyzoites, it has direct contact
with the host immune system, and induces strong anti-
body responses in both early and late stages of infec-
tion [12,15]. The antigenic properties of GRA7 make it
a good serological maker for the detection of anti-T.
gondii antibodies in chronic and acute infection.
ROC analysis enabled us to compare the relative sensi-
tivity and specificity of the developed ELSIAs at various
cut-offs, in which the AUC represents a statistical sum-
mary of the overall diagnostic performance of the test
[38,39]. In this study, the AUC of 0.973 for GRA7-ELISA
suggests that it represents a highly accurate test with good
discrimination of positive from negative samples, and the
cut-off at 0.809 showed the most appropriate sensitivity of
93.2% and specificity of 94.0%, respectively.
Conclusion
The present study, for the first time, evaluated the dense
granule antigens GRA1 and GRA7 as potential diagnos-
tic markers for T. gondii infection in dogs by ELISA,
showing that the GRA7-ELISA is highly sensitive and
specific, and that GRA7 is a potential serodiagnostic
marker for the detection of T. gondii infection in dogs.
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